Table 1:
Overview of Study Characteristics
| Study Characteristic | Number (Percent) of Trials | |
|---|---|---|
| Year | 2011 | 1 (2%) |
| 2012 | 2 (4%) | |
| 2013 | 4 (8%) | |
| 2014 | 8 (17%) | |
| 2015 | 3 (6%) | |
| 2016 | 5 (10%) | |
| 2017 | 3 (6%) | |
| 2018 | 5 (10%) | |
| 2019 | 7 (15%) | |
| 2020 | 4 (8%) | |
| 2021 | 6 (13%) | |
| Journal | AJRCCM | 2 (4%) |
| Chest | 2 (4%) | |
| Critical Care Medicine | 9 (19%) | |
| Intensive Care Medicine | 5 (10%) | |
| JAMA | 13 (27%) | |
| NEJM | 14 (29%) | |
| The Lancet | 3 (6%) | |
| Study Center | Single Center | 6 (13%) |
| Multicenter | 42 (88%) | |
| Funding * | Industry | 6 (13%) |
| Government | 25 (52%) | |
| Institution (e.g. University) | 6 (13%) | |
| Hospital | 0 (0%) | |
| None | 2 (4%) | |
| Other | 8 (17%) | |
| Intervention | Drug | 23 (48%) |
| Non-drug** | 25 (52%) | |
| Comparator | Usual Care | 26 (54%) |
| Active Comparator | 9 (19%) | |
| Placebo | 13 (27%) | |
| Subgroups | Outcomes Analyzed in Age Subgroup | 28 days all-cause mortality, Absence of functional impairment at 90 days, Number of Ventilator Free Days, Physical Functional Performance-10 longitudinally at various time points |
| Outcomes Analyzed in Frailty Subgroup | Ventilator-Associated Pneumonia | |
| Outcomes Analyzed in Multi-morbidity Subgroup | 28-day All-Cause Mortality, Physical Functional Performance-10 | |
*
Not reported for Igonin 2012.
**
Non drug interventions include: Body temperature targets, blood pressure target, Intensive Physiotherapy, Parenteral Nutrition
AJRCCM: American Journal of Respiratory and Critical Care Medicine. JAMA: Journal of American Medical Association. NEJM: New England Journal of Medicine.